Equities

Exelixis Inc

Exelixis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)36.25
  • Today's Change0.45 / 1.26%
  • Shares traded2.23m
  • 1 Year change+74.78%
  • Beta0.5174
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 29 2023202320222021
ASSETS
Cash And Short Term Investments9951,3081,467
Total Receivables, Net237215283
Total Inventory173327
Prepaid expenses686258
Other current assets, total------
Total current assets1,3181,6191,835
Property, plant & equipment, net362345149
Goodwill, net646464
Intangibles, net------
Long term investments729757371
Note receivable - long term1.321.661.67
Other long term assets1085367
Total assets2,9423,0712,616
LIABILITIES
Accounts payable343324
Accrued expenses218180231
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total14211282
Total current liabilities394324338
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total28425968
Total liabilities678583406
SHAREHOLDERS EQUITY
Common stock0.300.320.32
Additional paid-in capital2,4412,5372,428
Retained earnings (accumulated deficit)(173)(34)(217)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.75)(15)(0.76)
Total equity2,2642,4882,211
Total liabilities & shareholders' equity2,9423,0712,616
Total common shares outstanding303324319
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.